Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer’s disease

[1]  D. Wishart,et al.  Inter-Laboratory Robustness of Next-Generation Bile Acid Study in Mice and Humans: International Ring Trial Involving 12 Laboratories. , 2016, The journal of applied laboratory medicine.

[2]  Melissa A. Schilling.  Unraveling Alzheimer’s: Making Sense of the Relationship between Diabetes and Alzheimer’s Disease , 2016, Journal of Alzheimer's disease : JAD.

[3]  R. C. Aquino,et al.  The Role of Nutrition and Physical Activity in Cholesterol and Aging. , 2015, Clinics in geriatric medicine.

[4]  G. Kemmler,et al.  The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment , 2015, Alzheimer's & dementia.

[5]  J. Chiang,et al.  Bile Acid Signaling in Metabolic Disease and Drug Therapy , 2014, Pharmacological Reviews.

[6]  Derick R. Peterson,et al.  Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.

[7]  Sagheer Ahmad,et al.  Peripheral markers of Alzheimer's disease: Surveillance of white blood cells , 2013, Synapse.

[8]  Christian Humpel,et al.  Chronic vascular risk factors (cholesterol, homocysteine, ethanol) impair spatial memory, decline cholinergic neurons and induce blood–brain barrier leakage in rats in vivo , 2012, Journal of the Neurological Sciences.

[9]  Rainer Wilcken,et al.  Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2 , 2012, Proceedings of the National Academy of Sciences.

[10]  C. Humpel,et al.  Matrix metalloproteinase-2 and epidermal growth factor are decreased in platelets of Alzheimer patients. , 2012, Current Alzheimer research.

[11]  Murray Grossman,et al.  Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease , 2012, Neurology.

[12]  A. Reiss,et al.  Regulation of Cerebral Cholesterol Metabolism in Alzheimer Disease , 2012, Journal of Investigative Medicine.

[13]  G. Kemmler,et al.  Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer's Disease Patients from Healthy Subjects , 2011, Dementia and Geriatric Cognitive Disorders Extra.

[14]  J. Raufman,et al.  Bile Acids Regulate Cardiovascular Function , 2011, Clinical and translational science.

[15]  Christian Humpel,et al.  Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease? , 2011, Experimental Gerontology.

[16]  Christian Humpel,et al.  Identifying and validating biomarkers for Alzheimer's disease , 2011, Trends in biotechnology.

[17]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[18]  Andrew Lockhart,et al.  Cerebrospinal Fluid Steroidomics: Are Bioactive Bile Acids Present in Brain?* , 2009, The Journal of Biological Chemistry.

[19]  P. Sachdev,et al.  Plasma biomarkers for mild cognitive impairment and Alzheimer's disease , 2009, Brain Research Reviews.

[20]  Johan Auwerx,et al.  Targeting bile-acid signalling for metabolic diseases , 2008, Nature Reviews Drug Discovery.

[21]  A. Hofmann,et al.  Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics , 2008, Cellular and Molecular Life Sciences.

[22]  K. Anstey,et al.  Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[23]  K. Blennow.  CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment , 2005, Expert review of molecular diagnostics.

[24]  N. Mano,et al.  Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat brain Published, JLR Papers in Press, September 2, 2003. DOI 10.1194/jlr.M300369-JLR200 , 2004, Journal of Lipid Research.

[25]  Rudolph E. Tanzi,et al.  Alzheimer's disease: the cholesterol connection , 2003, Nature Neuroscience.

[26]  J. Chiang,et al.  Bile acid regulation of gene expression: roles of nuclear hormone receptors. , 2002, Endocrine reviews.

[27]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[28]  N. Butters,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery , 1994, Neurology.

[29]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[30]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[31]  A. Hofmann,et al.  A proposed nomenclature for bile acids. , 1992, Journal of lipid research.

[32]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[33]  G. Neale,et al.  Serum bile acids in liver disease , 1971, Gut.

[34]  C. Antunez,et al.  A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[35]  B. Staels,et al.  Role of bile acids and bile acid receptors in metabolic regulation. , 2009, Physiological reviews.

[36]  H. Bernstein,et al.  Bile acids as carcinogens in human gastrointestinal cancers. , 2005, Mutation research.

[37]  M. Folstein,et al.  Alzheimer's Disease in the National Academy of Sciences Registry of Aging Twin Veterans , 1990 .